P/E ratio for Seagen (SGEN)
P/E ratio as of September 2023 (TTM): -54.6
According to Seagen 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -54.6401. At the end of 2021 the company had a P/E ratio of -41.8.
P/E ratio history for Seagen from 2002 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -41.8 | -183.02% |
| 2020 | 50.3 | -142.73% |
| 2019 | -118 | 195.21% |
| 2018 | -39.9 | -35.11% |
| 2017 | -61.5 | 16.53% |
| 2016 | -52.8 | 10.53% |
| 2015 | -47.7 | -7.87% |
| 2014 | -51.8 | -32.44% |
| 2013 | -76.7 | 55.61% |
| 2012 | -49.3 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 8.40 | -115.38% | 🇺🇸 USA |
 AbbVie ABBV | 31.3 | -157.34% | 🇺🇸 USA |
 Biogen BIIB | 14.0 | -125.53% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 15.3 | -128.03% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 4.44 | -108.13% | 🇬🇧 UK |
 Spectrum Pharmaceuticals
SPPI | -2.86 | -94.76% | 🇺🇸 USA |
 ImmunoGen
IMGN | -21.4 | -60.85% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | -11.4 | -79.15% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.